{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"The primary efficacy endpoint of ORR consists of proportion of patients who achieve PR, VGPR, CR, or sCR according to IMWG 2016 criteria:\n\n* CR means Negative IFE of serum and urine, disappearance of any soft tissue plasmacytomas (SPD), and \\<5% plasma cells in bone marrow aspirates;\n* sCR means CR as defined above plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤ 4:1 or ≥ 1:2 for κ and λ patients, respectively, after counting ≥ 100 plasma cells);\n* VGPR means Serum and urine M-protein detectable by IFE but not on electrophoresis, or ≥90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours;\n* PR means ≥50% reduction of serum M-protein plus reduction in 24-hour urine M-protein by ≥90% or to \\<200 mg per 24 hours. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.","groups":[{"description":"Open-label ATG-010 80mg plus Dexamethasone 20 mg\n\nATG-010: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).\n\nDexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)","id":"OG000","title":"ATG-010 + Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"12 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}